BioCryst Pharmaceuticals Investor Relations Material
Latest events
Q4 2023
BioCryst Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from BioCryst Pharmaceuticals Inc
Access all reports
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company offers peramivir, an intravenous neuraminidase inhibitor, which completed Phase III clinical trial for the treatment of acute uncomplicated influenza in hospitalized adult and pediatric patients in Japan; BCX4161, an oral purine nucleoside phosphorylase (PNP) inhibitor for the treatment of hereditary angioedema; galidesivir, a broad spectrum viral RNA polymerase inhibitor that is under pre-clinical development against various high priority viruses associated with biodefense threat; and BCX9250 that is under pre-clinical development for the treatment of gout.
Key slides for BioCryst Pharmaceuticals Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
BioCryst Pharmaceuticals Inc
Q4 2023
BioCryst Pharmaceuticals Inc
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States